WC
AERI

Wexford Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Wexford Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,101
Closed -$42K – 393
2020
Q4 		$42K Buy
+3,101
New +$37.5K 0.01% 223
2019
Q3 		– Sell
-45,200
Closed -$1.34M – 162
2019
Q2 		$1.34M Buy
+45,200
New +$1.74M 0.16% 78

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Wexford Capital's AERI Position: Q1 2021 in Review

Wexford Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2021, closing a stake of 3,101 shares — an estimated $42K sold.

Wexford Capital first reported a position in AERI in Q2 2019 and held it in 2 quarters. The position peaked at $1.34M in Q2 2019. 158 funds tracked by Wall St. Rank hold AERI as of Q1 2021.

  • Wexford Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 3,101 Aerie Pharmaceuticals shares in Q1 2021, an estimated $42K.
  • Wexford Capital first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Wexford Capital's Aerie Pharmaceuticals position peaked at $1.34M in Q2 2019.
  • 158 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.